Evaluation of ivermectin effects on Covid-19

Evaluation effects of the standard regimen along with ivermectin on treatment of corona virus type 2 pneumonia

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190624043993N2

Enrollment

Registered

2020-07-12

Start date

2020-08-22

Completion date

Unknown

Last updated

2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type-2 coronavirus pneumonia. Severe acute respiratory syndrome [SARS]

Interventions

Intervention 1: Intervention group: Patients will recieved ivermectin (150mcg/kg/day) along with the standard of care. Intervention 2: Control group: Patients will received the standard of care accord

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Definite (clinical and positive PCR) Covid-19 disease Less than 48 hours have passed since the onset of symptoms

Exclusion criteria

Exclusion criteria: Underlying liver disease/hepatitis Underlying hematological disorders Seizures and encephalopathy Known allergies to ivermectin Pregnancy/lactation Patients who themselves or their legal guardians are reluctant to participate or continue clinical trials

Design outcomes

Primary

Measure	Time frame
Clinical response. Timepoint: Day 7 and 14 after study initiation. Method of measurement: Clinical- radiographic.	—

Secondary

Measure	Time frame
Virological response. Timepoint: Day 7. Method of measurement: PCR.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactForoud Shahbazi

Kermanshah University of Medical Sciences

Foroud08@gmail.com+98 83 3426 6780

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026